Serum biomarkers and clinical characteristics of patients with Hodgkin lymphoma

Olivera  Simonović; Milena Todorović; Biljana Mihaljević; Tatjana Stoimenov-Jevtović; Ivan Petković; Lana Mačukanović -Golubović; Goran Marjanović

doi:10.2298/VSP160705018S

Olivera Simonović Clinical Center Niš, *Clinic for Hematology and Clinical Immunology, Niš, Serbia
Milena Todorović Clinical Center of Serbia, Clinic of Hematology, Belgrade, Serbia
Biljana Mihaljević Clinical Center of Serbia, Clinic of Hematology, Belgrade, Serbia
Tatjana Stoimenov-Jevtović University of Niš, Faculty of Medicine, Niš, Serbia
Ivan Petković University of Niš, Faculty of Medicine, Niš, Serbia
Lana Mačukanović -Golubović University of Niš, Faculty of Medicine, Niš, Serbia
Goran Marjanović Clinical Center Niš, Clinic for Hematology and Clinical Immunology, Niš, Serbia; University of Niš, Faculty of Medicine, Niš, Serbia

DOI: https://doi.org/10.2298/VSP160705018S

Keywords: hodgkin disease;, biomarkers, tumor;, enzyme-linked immunosorbent assay;, treatment outcome;, prognosis.

Abstract

Background/Aim. In classical Hodgkin’s lymphoma (cHL) the existing prognostic scoring systems do not include markers that adequately reflect the interaction of malignant Hodgkin and Reed-Sternberg (HRS) cells and tumor environment. The aim of this study was to determine the relationship between serum Galectin-1 (Gal-1) and soluble CD163 (sCD163) and the clinical status of patients with cHL, with special emphasis on the presence of relapse, progression, or resistance to the therapy applied. Methods. The research included 79 patients of whom 63 were patients with cHL, and the control group of 16 healthy volunteers. The study group of 63 patients with cHL included a subgroup of newly diagnosed patients without therapy, newly diagnosed patients with therapy, patients with relapse and progression of the disease and primary refractory patients during 2014 and 2015. Results. Analysis of the levels of sCD163 and Gal-1 within a group of patients suffering from cHL showed that the values of both molecules were higher in relapsed patients and the subgroup with progressive disease comparing to the subgroup of newly diagnosed patients without therapy or patients with therapy onset. Conclusion. Determination of Gal-1 and sCD163 levels is simple and reliable analysis that can contribute to the identification of high-risk patients with cHL and deserves inclusion in current prognostic scoring systems.

Author Biographies

Olivera Simonović, Clinical Center Niš, *Clinic for Hematology and Clinical Immunology, Niš, Serbia

specialist of internal medicine, subspecialist in hemathology

Milena Todorović, Clinical Center of Serbia, Clinic of Hematology, Belgrade, Serbia

PhD, specialist of internal medicine, subspecialist in hematology

Biljana Mihaljević, Clinical Center of Serbia, Clinic of Hematology, Belgrade, Serbia

PhD, specialist of internal medicine, subspecialist in hematology

Tatjana Stoimenov-Jevtović, University of Niš, Faculty of Medicine, Niš, Serbia

associate professor of biochemistry

Ivan Petković, University of Niš, Faculty of Medicine, Niš, Serbia

specialist of internal medicine

Lana Mačukanović -Golubović, University of Niš, Faculty of Medicine, Niš, Serbia

profesor interne medicine

Goran Marjanović, Clinical Center Niš, Clinic for Hematology and Clinical Immunology, Niš, Serbia; University of Niš, Faculty of Medicine, Niš, Serbia

professor of internal medicine

References

Pileri SA, Ascani S, Leoncini L, Sabattini E, Zinzani PL, Pic¬caluga PP, et al. Hodgkin's lymphoma the pathologist's viewpoint. J Clin Pathol 2002; 55(3): 161‒76.

Hnátková M, Mociková H, Trnený M, Zivný J. The biologi¬cal en-vironment of Hodgkin's lymphoma and the role of the chem-okine CCL17/TARC. Prague Med Rep 2009; 110(1): 35‒41.

de la Cruz-Merino L, Lejeune M, Nogales Fernández E, Henao Carrasco F, Grueso López A, Illescas Vacas A, et al. Role of im-mune escape mechanisms in Hodgkin's lymphoma de-velopment and progression: a whole new world with therapeu-tic implications. Clin Dev Immunol 2012; 2012: 756353.

Smolewski P, Robak T, Krykowski E, Blasiñska-Morawiec M, Niewiadomska H, Pluzanska A, et al. Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res 2000; 6(3): 1150‒60.

Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin On-col 2002; 20(1): 221‒30.

Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Pro¬ject on Advanced Hodgkin's Disease. N Engl J Med 1998; 339(21): 1506‒14.

Zhang B, Yao G, Zhang Y, Gao J, Yang B, Rao Z, et al. M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphan¬giogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 2011; 66(11): 1879‒86.

Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macro-phage polarization: Tumor-associated macrophages as a para-digm for polarized M2 mononuclear phagocytes. Trends Im-munol 2002; 23(11): 549‒55.

Jones K, Vari F, Keane C, Crooks P, Nourse JP, Seymour LA, et al. Serum CD163 and TARC as disease response bio¬markers in classical Hodgkin lymphoma. Clin Cancer Res 2013; 19(3): 731‒42.

Tsai C, Chiu Y, Hsu T, Lin-Ying I, Hsieh S, Lin KI. Galectin-1 promotes immunoglobulin production during plasma cell dif-ferentiation. J Immunol 2008; 181(7): 4570‒9.

Maeda K, Hazama S, Tokuno K, Kan S, Maeda Y, Watanabe Y, et al. Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity. Anticancer Res 2011; 31(12): 4569‒74.

Ouyang J, Plütschow A, Pogge von Strandmann E, Reiners KS, Ponad-er S, Rabinovich GA, et al. Galectin-1 serum lev¬els reflect tu-mor burden and adverse clinical features in classical Hodgkin lymphoma. Blood 2013; 121(17): 3431‒3.

Kamper P, Ludvigsen M, Bendix K, Hamilton-Dutoit S, Rabi¬novich GA, Møller MB, et al. Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood 2011; 117(24): 6638‒49.

Plattel WJ, Alsada ZN, Imhoff GW, Diepstra A, Berg A, Vis¬ser L. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: Comparison of sGalectin-1, sCD163 and sCD30 with TARC. Br J Haematol 2016; 175(5): 868‒75.

Verschuere T, van Woensel M, Fieuws S, Lefranc F, Mathieu V, Kiss R, et al. Altered galectin-1 serum levels in patients diag-nosed with high-grade glioma. J. Neurooncol 2013; 115(1): 9‒17.